
Vincenzo Cerullo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9527628/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor–Modified T Cells in Solid Tumors. Cancer Research, 2014, 74, 5195-5205.	0.4	269
2	Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF. Molecular Therapy, 2010, 18, 1874-1884.	3.7	201
3	Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients. Cancer Research, 2010, 70, 4297-4309.	0.4	197
4	Ischemic Neoangiogenesis Enhanced by \hat{I}^2 2 -Adrenergic Receptor Overexpression. Circulation Research, 2005, 97, 1182-1189.	2.0	154
5	Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus. Clinical Cancer Research, 2013, 19, 2734-2744.	3.2	150
6	Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients. Molecular Therapy, 2013, 21, 1212-1223.	3.7	146
7	Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus. Cancer Research, 2012, 72, 2327-2338.	0.4	144
8	Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus. Molecular Therapy, 2011, 19, 1737-1746.	3.7	141
9	Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Therapy, 2012, 19, 988-998.	2.3	132
10	Toll-like Receptor 9 Triggers an Innate Immune Response to Helper-dependent Adenoviral Vectors. Molecular Therapy, 2007, 15, 378-385.	3.7	130
11	Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients. Cancer Research, 2012, 72, 1621-1631.	0.4	117
12	PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Therapy, 2005, 12, 579-587.	2.3	115
13	Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. Journal of Cell Biology, 2008, 181, 803-816.	2.3	106
14	Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors. Clinical Cancer Research, 2010, 16, 3035-3043.	3.2	97
15	Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. Journal of Controlled Release, 2018, 283, 223-234.	4.8	95
16	Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice. Journal of Controlled Release, 2019, 294, 165-175.	4.8	93
17	AKT Participates in Endothelial Dysfunction in Hypertension. Circulation, 2004, 109, 2587-2593.	1.6	89
18	Artificially cloaked viral nanovaccine for cancer immunotherapy. Nature Communications, 2019, 10, 5747.	5.8	86

#	Article	IF	CITATIONS
19	An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor Clearance. Molecular Therapy, 2012, 20, 2076-2086.	3.7	84
20	Design and application of oncolytic viruses for cancer immunotherapy. Current Opinion in Biotechnology, 2020, 65, 25-36.	3.3	84
21	Integrin targeted oncolytic adenoviruses Ad5â€D24â€RGD and Ad5â€RGDâ€D24â€GMCSF for treatment of patie with advanced chemotherapy refractory solid tumors. International Journal of Cancer, 2012, 130, 1937-1947.	nts 2.3	82
22	Oncolytic vaccinia virus for the treatment of cancer. Expert Opinion on Biological Therapy, 2011, 11, 595-608.	1.4	78
23	Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. Oncolmmunology, 2016, 5, e1105429.	2.1	70
24	Genetic diversity and tumor immunesurveillance. Journal of Thoracic Disease, 2013, 5, 6-7.	0.6	66
25	Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer. Molecular Therapy, 2012, 20, 1821-1830.	3.7	64
26	Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Therapy, 2010, 17, 892-904.	2.3	61
27	Oncolytic Adenoviruses for Cancer Immunotherapy. Advances in Cancer Research, 2012, 115, 265-318.	1.9	61
28	Immune Response to Helper Dependent Adenoviral Mediated Liver Gene Therapy: Challenges and Prospects. Current Gene Therapy, 2007, 7, 297-305.	0.9	60
29	Oncolytic Viruses for Induction of Anti-Tumor Immunity. Current Pharmaceutical Biotechnology, 2012, 13, 1750-1760.	0.9	56
30	The Evolution of Adenoviral Vectors through Genetic and Chemical Surface Modifications. Viruses, 2014, 6, 832-855.	1.5	53
31	Oncolytic adenovirus based on serotype 3. Cancer Gene Therapy, 2011, 18, 288-296.	2.2	51
32	Oncolytic adenovirus and doxorubicinâ€based chemotherapy results in synergistic antitumor activity against softâ€ŧissue sarcoma. International Journal of Cancer, 2015, 136, 945-954.	2.3	51
33	Antiangiogenic Arming of an Oncolytic Vaccinia Virus Enhances Antitumor Efficacy in Renal Cell Cancer Models. Journal of Virology, 2010, 84, 856-866.	1.5	50
34	Generation of Helper-Dependent Adenoviral Vectors by Homologous Recombination. Molecular Therapy, 2002, 5, 204-210.	3.7	49
35	Synergistic antiâ€tumor efficacy of immunogenic adenovirus ONCOSâ€102 (Ad5/3â€D24â€GMâ€CSF) and stand of care chemotherapy in preclinical mesothelioma model. International Journal of Cancer, 2016, 139, 1883-1893.	ard 2.3	46
36	Patient-Derived Organoids for Precision Cancer Immunotherapy. Cancer Research, 2021, 81, 3149-3155.	0.4	46

#	Article	IF	CITATIONS
37	Correction of Murine Hemophilia A and Immunological Differences of Factor VIII Variants Delivered by Helper-dependent Adenoviral Vectors. Molecular Therapy, 2007, 15, 2080-2087.	3.7	45
38	Induction of Interferon Pathways Mediates In Vivo Resistance to Oncolytic Adenovirus. Molecular Therapy, 2011, 19, 1858-1866.	3.7	42
39	Immunological Effects of a Tumor Necrosis Factor Alpha–Armed Oncolytic Adenovirus. Human Gene Therapy, 2015, 26, 134-144.	1.4	42
40	Dual-peptide functionalized acetalated dextran-based nanoparticles for sequential targeting of macrophages during myocardial infarction. Nanoscale, 2020, 12, 2350-2358.	2.8	42
41	Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM SF: <scp>R</scp> esults <i>in vitro</i> , in rodents and in humans. International Journal of Cancer, 2015, 137, 1775-1783.	2.3	41
42	Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity. Molecular Cancer Therapeutics, 2016, 15, 651-660.	1.9	41
43	Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses. Molecular Therapy, 2018, 26, 2315-2325.	3.7	41
44	Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy. Cancer Research, 2020, 80, 2575-2585.	0.4	39
45	Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1. Clinical Cancer Research, 2010, 16, 2540-2549.	3.2	37
46	Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir. Journal of Gene Medicine, 2010, 12, 435-445.	1.4	36
47	Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. International Journal of Cancer, 2014, 135, 720-730.	2.3	36
48	Antitumorâ€specific Tâ€cell responses induced by oncolytic adenovirus ONCOSâ€102 (AdV5/3â€D24â€GMâ€CSF peritoneal mesothelioma mouse model. Journal of Medical Virology, 2018, 90, 1669-1673.	⁻) in 2.5	36
49	Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor. ACS Nano, 2019, 13, 6477-6490.	7.3	36
50	Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment. PLoS ONE, 2017, 12, e0182715.	1.1	34
51	Synthesis and biological evaluation of unprecedented ring-expanded nucleosides (RENs) containing the imidazo[4,5-d][1,2,6]oxadiazepine ring system. Chemical Communications, 2012, 48, 9310.	2.2	33
52	Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. Acta Oncológica, 2010, 49, 120-122.	0.8	32
53	CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging. Gene Therapy, 2014, 21, 195-204.	2.3	32
54	Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity. Molecular Therapy - Oncolytics, 2016, 3, 16002.	2.0	32

#	Article	IF	CITATIONS
55	MyD88-Dependent Silencing of Transgene Expression During the Innate and Adaptive Immune Response to Helper-Dependent Adenovirus. Human Gene Therapy, 2010, 21, 325-336.	1.4	31
56	Oncolytic adenoviruses. Oncolmmunology, 2012, 1, 979-981.	2.1	31
57	Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors. Oncolmmunology, 2018, 7, e1457596.	2.1	31
58	Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. Journal of Gene Medicine, 2011, 13, 253-261.	1.4	30
59	Short-term Correction of Arginase Deficiency in a Neonatal Murine Model With a Helper-dependent Adenoviral Vector. Molecular Therapy, 2009, 17, 1155-1163.	3.7	29
60	Metastatic state of parent cells influences the uptake and functionality of prostate cancer cellâ€derived extracellular vesicles. Journal of Extracellular Vesicles, 2017, 6, 1354645.	5.5	29
61	Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process. Cancers, 2020, 12, 1660.	1.7	29
62	Extracellular vesicles provide a capsidâ€free vector for oncolytic adenoviral DNA delivery. Journal of Extracellular Vesicles, 2020, 9, 1747206.	5.5	27
63	Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform. Molecular Therapy - Oncolytics, 2021, 20, 459-469.	2.0	27
64	Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. , 2021, 9, e003000.		27
65	Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. Molecular Therapy, 2016, 24, 175-183.	3.7	26
66	Defects in Innate Immunity Render Breast Cancer Initiating Cells Permissive to Oncolytic Adenovirus. PLoS ONE, 2010, 5, e13859.	1.1	25
67	Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures. European Journal of Cancer, 2010, 46, 625-635.	1.3	25
68	Capsid-Modified Adenoviral Vectors for Improved Muscle-Directed Gene Therapy. Human Gene Therapy, 2012, 23, 1065-1070.	1.4	25
69	A novel <i>in silico</i> framework to improve MHC-I epitopes and break the tolerance to melanoma. Oncolmmunology, 2017, 6, e1319028.	2.1	25
70	Peptide Nucleic Acid-Functionalized Adenoviral Vectors Targeting G-Quadruplexes in the P1 Promoter of Bcl-2 Proto-Oncogene: A New Tool for Gene Modulation in Anticancer Therapy. Bioconjugate Chemistry, 2019, 30, 572-582.	1.8	25
71	Antigen-Specific Tolerance of Humanα1-Antitrypsin Induced by Helper-Dependent Adenovirus. Human Gene Therapy, 2007, 18, 1215-1224.	1.4	24
72	GMCSFâ€armed vaccinia virus induces an antitumor immune response. International Journal of Cancer, 2015, 136, 1065-1072.	2.3	23

#	Article	IF	CITATIONS
73	Treatment of osteoarthritis using a helper-dependent adenoviral vector retargeted to chondrocytes. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16008.	1.8	23
74	Neonatal Fc receptor-targeted lignin-encapsulated porous silicon nanoparticles for enhanced cellular interactions and insulin permeation across the intestinal epithelium. Bioactive Materials, 2022, 9, 299-315.	8.6	23
75	NOD2 Signaling Contributes to the Innate Immune Response Against Helper-Dependent Adenovirus Vectors Independently of MyD88 <i>In Vivo</i> . Human Gene Therapy, 2011, 22, 1071-1082.	1.4	22
76	PEGylated helper-dependent adenoviral vector expressing human Apo A-I for gene therapy in LDLR-deficient mice. Gene Therapy, 2013, 20, 1124-1130.	2.3	22
77	Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma. Cancer Immunology Research, 2021, 9, 981-993.	1.6	22
78	A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines. ELife, 2022, 11, .	2.8	21
79	Dendritic Cell Function After Gene Transfer with Adenovirus-calcium Phosphate Co-precipitates. Molecular Therapy, 2007, 15, 386-392.	3.7	20
80	Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment. , 2022, 236, 108103.		20
81	Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy. Molecular Therapy - Oncolytics, 2014, 1, 14008.	2.0	19
82	Bioengineered Factor IX Molecules with Increased Catalytic Activity Improve the Therapeutic Index of Gene Therapy Vectors for Hemophilia B. Human Gene Therapy, 2009, 20, 479-485.	1.4	18
83	Oncolytic Adenoviruses for Cancer Therapy. International Journal of Molecular Sciences, 2021, 22, 2517.	1.8	18
84	Serotype Chimeric and Fiber-Mutated Adenovirus Ad5/19p-HIT for Targeting Renal Cancer and Untargeting the Liver. Human Gene Therapy, 2009, 20, 611-620.	1.4	17
85	In vivoandin vitrodistribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments. Annals of Medicine, 2011, 43, 151-163.	1.5	17
86	PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification. ACS Nano, 2021, 15, 15992-16010.	7.3	17
87	Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation. Briefings in Bioinformatics, 2022, 23, .	3.2	17
88	Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks. International Journal of Molecular Sciences, 2019, 20, 621.	1.8	16
89	Tumor Suppressor Role of hsa-miR-193a-3p and -5p in Cutaneous Melanoma. International Journal of Molecular Sciences, 2020, 21, 6183.	1.8	16
90	Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy. Cancers, 2021, 13, 3408.	1.7	16

#	Article	IF	CITATIONS
91	Discovery of a new PCC-mediated stereoselective oxidative spiroketalization process. An access to a new type of poly-THF spiroketal compound displaying anticancer activity. Organic and Biomolecular Chemistry, 2009, 7, 3036.	1.5	13
92	Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment. Journal of Translational Medicine, 2013, 11, 193.	1.8	13
93	In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders. International Journal of Cancer, 2014, 134, 2878-2890.	2.3	13
94	Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System. Current Cancer Drug Targets, 2018, 18, 124-138.	0.8	13
95	Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site. , 2019, 7, 174.		13
96	Circulating microRNAs as biomarkers for early diagnosis of cutaneous melanoma. Expert Review of Molecular Diagnostics, 2020, 20, 19-30.	1.5	13
97	Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin. , 2021, 9, e002707.		12
98	Discovery of a novel one-step RuO4-catalysed tandem oxidative polycyclization/double spiroketalization process. Access to a new type of polyether bis-spiroketal compound displaying antitumour activity. Tetrahedron, 2010, 66, 9370-9378.	1.0	11
99	Influence of Cell Membrane Wrapping on the Cellâ^'Porous Silicon Nanoparticle Interactions. Advanced Healthcare Materials, 2020, 9, e2000529.	3.9	11
100	Surfaceome and Exoproteome Dynamics in Dual-Species Pseudomonas aeruginosa and Staphylococcus aureus Biofilms. Frontiers in Microbiology, 2021, 12, 672975.	1.5	11
101	Effects of capsidâ€modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer. International Journal of Cancer, 2012, 131, 253-263.	2.3	10
102	Beyond Gene Delivery: Strategies to Engineer the Surfaces of Viral Vectors. Biomedicines, 2013, 1, 3-16.	1.4	10
103	β2-Integrin Adhesion Regulates Dendritic Cell Epigenetic and Transcriptional Landscapes to Restrict Dendritic Cell Maturation and Tumor Rejection. Cancer Immunology Research, 2021, 9, 1354-1369.	1.6	10
104	Helper-dependent adenovirus-mediated gene transfer of a secreted LDL receptor/transferrin chimeric protein reduces aortic atherosclerosis in LDL receptor-deficient mice. Gene Therapy, 2019, 26, 121-130.	2.3	9
105	Pathogens: Our Allies against Cancer?. Molecular Therapy, 2021, 29, 10-12.	3.7	9
106	Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model. Frontiers in Oncology, 0, 12, .	1.3	9
107	Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy. Molecular Therapy - Oncolytics, 2014, 1, 14006.	2.0	8
108	Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy. PLoS ONE, 2019, 14, e0224072.	1.1	8

#	Article	IF	CITATIONS
109	GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses. Molecular Therapy - Methods and Clinical Development, 2021, 20, 625-634.	1.8	8
110	Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine. Frontiers in Immunology, 2022, 13, 826164.	2.2	8
111	Synthesis and Evaluation of the Antiproliferative Properties of a Tethered Tubercidin–Platinum(II) Complex. European Journal of Organic Chemistry, 2015, 2015, 7550-7556.	1.2	6
112	A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella. Molecular Therapy - Oncolytics, 2022, 25, 137-145.	2.0	5
113	Safety of Glucocorticoids in Cancer Patients Treated with Oncolytic Adenoviruses. Molecular Pharmaceutics, 2011, 8, 93-103.	2.3	4
114	661. Synergistic Anti-Tumor Efficacy of Immunogenic Adenovirus ONCOS-102 and Standard of Care Chemotherapy in Preclinical Mesothelioma Model. Molecular Therapy, 2016, 24, S262.	3.7	3
115	Oncolytic adenoviruses coated with MHC-I tumor epitopes for a new oncolytic vaccine platform. , 2015, 3, .		2
116	Viral Nanoparticles: Cancer Vaccines and Immune Modulators. Advances in Experimental Medicine and Biology, 2021, 1295, 317-325.	0.8	2
117	Calcium Gluconate in Phosphate Buffered Saline Increases Gene Delivery with Adenovirus Type 5. PLoS ONE, 2010, 5, e13103.	1.1	2
118	71. Boosting the Immunogenicity of an Oncolytic Vaccinia Virus By Expression of DAI Can Enhance Anti-Tumor Immunity in Humanized Mice. Molecular Therapy, 2015, 23, S31.	3.7	1
119	408. Oncolytic Vaccines in Combination with PD-L1 Blockade for the Treatment of Melanoma. Molecular Therapy, 2016, 24, S161-S162.	3.7	1
120	Abstract A034: Boosting the efficacy of PD-L1 blockade with oncolytic vaccine for improved antitumor responses in melanoma. , 2016, , .		1
121	220. Evaluation of the Efficacy of a New Oncolytic Vaccine Platform in Humanized Mice. Molecular Therapy, 2015, 23, S86-S87.	3.7	0
122	622. Oncolytic Adenoviruses Loaded With Active Drugs as a Novel Drug Delivery System for Cancer Therapy. Molecular Therapy, 2015, 23, S247.	3.7	0
123	665. Toxicity and Bio-Distribution of a GM-CSF-Expressing, Chimeric Oncolytic Adenovirus ONCOS-102. Molecular Therapy, 2015, 23, S264-S265.	3.7	0
124	Improving the efficacy of PDL1 blockade by combination with oncolytic vaccines. Annals of Oncology, 2016, 27, viii2.	0.6	0
125	659. Oncolytic Adenovirus Loaded with Bioactive Modified Peptide as a Novel Approach to Treat Cancer. Molecular Therapy, 2016, 24, S261.	3.7	0
126	642. Oncolytic Vaccines with Modified Tumor Epitopes for Cancer Immunotherapy. Molecular Therapy, 2016, 24, S254.	3.7	0

#	Article	IF	CITATIONS
127	Enhanced anti-cancer vaccines with a new epitope improvement system. Annals of Oncology, 2016, 27, viii2.	0.6	0
128	Homology between cancer and viral epitopes as criteria to design improved cancer vaccines. Annals of Oncology, 2017, 28, xi18.	0.6	0
129	Abstract 1488: Viral molecular mimicry influences the antitumor immune response in murine and human melanoma. , 2021, , .		0
130	Abstract 1897: PeptiCHIP: A novel microfluidic-based chip platform for tumor antigen landscape identification. , 2021, , .		0
131	Abstract 1867: Characterization in patient derived tumor organoids of novel oncolytic adenoviruses expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitors. , 2021, , .		0
132	CGTG-102 (Ad5/3-D24-GMCSF), a novel oncolytic adenovirus, in patients with refractory solid tumors: Experience from an advanced therapy access program Journal of Clinical Oncology, 2012, 30, e13035-e13035.	0.8	0
133	Abstract 3304: Oncolytic adenovirus with low-dose temozolomide induces autophagy and antitumor immune responses preclinically and in cancer patients , 2013, , .		0
134	Oncolytic Viruses for Treatment of Cancer. , 2015, , 185-200.		0
135	Abstract B51: Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans. , 2015, , .		0
136	Abstract B123: Local treatment with PeptiCRAd-1, a novel cancer immunotherapy approach, mediates a systemic antitumour CD8+ T-cell response and infiltration of CD8+ and CD4+ T-cells into distant untreated tumors in a clinically relevant humanized mouse melanoma model. , 2019, , .		0
137	Oncolytic viruses for antigen delivery. , 2022, , 1-19.		0